Adam Friedman

CLOSE

Adam Friedman, M.D., Ph.D.

PRESIDENT, CORPORATE STRATEGY & BUSINESS DEVELOPMENT

Dr. Adam Friedman is an accomplished physician, scientist and life sciences entrepreneur with extensive experience in oncology. He currently serves as President, Corporate Strategy & Business Development, which follows his former role as interim CEO of Scorpion Therapeutics.

Prior to joining the company, Dr. Friedman served as Director at Serien Therapeutics, a next-generation immuno-metabolism company, and founder of Vivid Biosciences, an oncology platform discovery company, where he served as President and Chief Executive Officer. As an entrepreneur-in-residence at Atlas Venture, he helped launch several portfolio companies exploring new areas of biology, including Raze Therapeutics, a next-generation cancer metabolism company, where he served as Founder & Director of Corporate Development. He has authored multiple peer-reviewed publications on systems biology, cell signaling, genetics and cancer biology.

Dr. Friedman received his B.A. in molecular biology from Princeton University and received both his M.D. and Ph.D. in genetics from Harvard Medical School. Dr. Friedman completed residency training in pediatrics at Boston Children’s Hospital.